Latest News

JP Morgan’s downgrade of Cognex (CGNX) to a more cautious rating has put the stock back under the microscope, as investors reassess how its automation story lines up with near term growth expectations. See our latest analysis for Cognex. The downgrade lands after a choppy stretch, with a 30 day share price return of minus 9.62 percent and a 5 year total shareholder return of minus 47.58 percent, signaling that momentum has been fading despite recent operational progress. If this shift in...

If you are wondering whether Hudbay Minerals is still a smart buy after its huge run up, you are not alone. This is exactly where valuation starts to matter most. The stock is up 4.3% over the last week, 9.0% over the past month, and an eye catching 98.0% year to date, building on a 94.1% 1 year gain and a massive 234.8% return over 3 years. Much of this momentum has been driven by stronger copper sentiment and renewed interest in miners leveraged to long term electrification themes, with...

Wondering if Kellanova is still fairly priced after its long run, or if there is more upside left in the tank? This breakdown will help you decide whether the current share price actually makes sense. The stock has been mostly treading water in the short term, down 0.6% over the last week and roughly flat over the past month at 0.1%. However, that hides a steadier climb of 2.6% year to date and 6.2% over the last year, compounding into 32.5% and 69.5% gains over the past 3 and 5...

First Mining Gold (TSX:FF) is back on investors radar as it advances engineering and community work at its flagship Springpole project, following an updated study that sharpened the project plan and regional alignment. See our latest analysis for First Mining Gold. Those Springpole updates seem to be landing with investors, with the stock’s recent 90 day share price return of 128.57 percent and year to date share price return of 300 percent backing a 269.23 percent one year total shareholder...

TJX Companies (TJX) just posted another solid quarter, with Q3 2026 revenue of about $15.1 billion, Basic EPS of $1.28, and net income of $1.4 billion setting the tone for its latest update. The company has seen revenue move from roughly $14.1 billion and EPS of $1.15 in Q3 2025 to $15.1 billion and $1.28 this quarter, while trailing twelve month revenue has climbed to about $59.0 billion alongside EPS of $4.58 and net income of $5.1 billion, giving investors a clear view of steady top and...

RLI (RLI) has quietly slipped this year, with the stock down about 23% year to date even as its long term track record and underwriting discipline remain intact. This creates an interesting setup for patient investors. See our latest analysis for RLI. The 6.8% 1 month share price return suggests some buyers are stepping back in after a weak start to the year, even though the year to date share price return is still firmly negative and the 1 year total shareholder return trails its solid 3 and...

Whether you are wondering if Daiichi Sankyo Company is starting to look like good value after a rough stretch, or if the market still sees more downside ahead, this breakdown will help you sort signal from noise. The stock is down 7.8% over the last week, 2.9% over the last month, and a steep 26.2% over the past year, even though long term holders over 5 years are still sitting on a 10.7% gain. Recent headlines have focused on Daiichi Sankyo's expanding oncology portfolio and major global...

Oppenheimer recently initiated coverage on Theravance Biopharma with an Outperform rating, emphasizing the importance of the Phase 3 ampreloxetine readout expected in the first quarter of 2026 and the company’s virtual key opinion leader event on this program. The focus on ampreloxetine as a potential billion-dollar therapy in a rare neurogenic condition highlights how pivotal this single late-stage asset has become for Theravance’s future prospects and risk profile. We’ll now explore how...

If you have been wondering whether AtkinsRéalis Group is still good value after its huge run up, you are not alone. This stock has become a favorite talking point for investors trying to separate momentum from true underlying worth. Even after pulling back around 11.4% over the last month and slipping 0.4% in the past week, the share price is still up 16.0% year to date, 13.2% over the last year and an impressive 254.5% over three years and 279.4% over five years. This naturally raises the...

If you are wondering whether Novavax at around $6.84 is a beaten down bargain or a value trap, you are not alone. That is exactly what this breakdown is going to tackle. The stock has slipped recently, with returns of about -1.6% over the last week, -13.5% over the last month and -20.2% year to date, on top of a rough -94.1% over five years. Those moves reflect shifting sentiment around Novavax's vaccine pipeline and its ability to carve out a sustainable niche in a post pandemic market...

Wondering if Amneal Pharmaceuticals is still a smart buy after its big run, or if most of the upside is already priced in? Here is a breakdown of what the recent market action is really telling us about its value. The stock has cooled slightly in the last week, down 2.6%, but that comes after a strong 8.9% gain over 30 days, a hefty 57.1% year to date, and an impressive 425.4% over three years. Those moves follow a steady stream of developments around Amneal strengthening its position in...

Wondering if CBIZ is now a bargain or a value trap after its recent slide? This article will walk through the numbers so you can decide with confidence. The stock has bounced 4.9% over the last week, but that is against a much steeper backdrop of a 6.7% drop over 30 days and a painful 36.6% fall year to date, leaving 1 year returns at around -38.4% despite a strong 102.5% gain over 5 years. Those moves have come as investors reassess service focused businesses like CBIZ in a higher rate,...

If you are wondering whether Teladoc Health is a beaten-down disaster or a quietly emerging value play at today’s price, you are not alone. That is exactly what this breakdown is here to unpack. The stock has bounced 1.1% over the last week but is still down 7.5% over the past month and a steep 20.9% year to date, capping a brutal 96.1% slide over five years that has reset investor expectations. Those moves have come as Teladoc tries to reposition itself from a hyper-growth pandemic favorite...

Saba Capital Management’s latest insider buy in ASA Gold and Precious Metals (ASA), adding over 9,000 shares at around 53 dollars each, puts fresh attention on what this big shareholder might be seeing in the period ahead. See our latest analysis for ASA Gold and Precious Metals. That conviction lines up with a powerful run in ASA’s share price, which now sits at 52.76 dollars after a roughly 14 percent 1 month share price return and a standout 1 year total shareholder return of about 160...

In its most recent Q3 update, Marqeta reported year-on-year revenue growth of 27.6% and outperformed analyst estimates for both revenue and EBITDA, supported by stronger-than-expected total payment volume. This outperformance underscores how Marqeta’s card-issuing platform can convert higher transaction activity into improving profitability metrics, an important signal for long-term scalability. We’ll now examine how Marqeta’s better-than-expected Q3 revenue and EBITDA performance may...

Arbor Realty Trust recently drew attention after Director William Green bought 12,800 shares on November 28, 2025, adding to a year-long pattern of insider purchases with no reported insider sales. At the same time, analysts have lowered earnings estimates for the current and next fiscal years, highlighting a tension between insider confidence and market caution around Arbor Realty Trust’s outlook. We’ll now examine how this steady insider buying interest may influence Arbor Realty Trust’s...

PNB Housing Finance Limited's ( NSE:PNBHOUSING ) price-to-earnings (or "P/E") ratio of 10.6x might make it look like a...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Key Insights Significant control over Arvind Fashions by private companies implies that the general public has more...

Key Insights Indian Oil's significant state or government ownership suggests that the key decisions are influenced by...

Micronics Japan Co., Ltd. ( TSE:6871 ) will increase its dividend from last year's comparable payment on the 30th of...

With its stock down 9.2% over the past month, it is easy to disregard Oberoi Realty (NSE:OBEROIRLTY). However, a closer...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Key Insights The projected fair value for Tata Chemicals is ₹1,157 based on 2 Stage Free Cash Flow to Equity Tata...